Pall launches pyrofree sterile, ready-to-use glass vials
The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines.
Pall Life Sciences’ is formally launching its Pyrofree glass vial line for sterile, flexible filling from 2 mL to 20 mL at PDA.
The Pyrofree vials product range is a unique solution providing filling processes with ready-to-use glass vials depyrogenated and sterilized according to industrial operations methods applied in vaccines, biotechnology, and pharmaceutical industries, and in hospitals. The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines. The Pyrofree vials product range offers a unique opportunity to simplify, facilitate and accelerate the filling of these products.
A pyrogen is defined as any substance that can cause a fever, such as endotoxins. The injection of endotoxins into the blood can cause severe hazard to a patient and in worst case, lead to septic shock. Depyrogenation, or the removal of pyrogens, is therefore a crucial need in the aseptic filling process of parenteral drugs. Primary packaging of injectable drugs is particularly controlled for the absence of pyrogens and any chemical agent which may alter drug substances properties and stability. In this case, sterilization of primary packaging (e.g., by ethylene oxide sterilization) represents a risk of introducing chemical agents into drug substances.
The Pyrofree vials product range addresses these needs thanks to its unique packaging technology, allowing sterilization and depyrogenation of the vials by dry heat in their primary packaging under vacuum. The Pyrofree process results in ready-to-use vials which can be used for the filling of injectable drugs without using washing and depyrogenation equipment from the filling line.
The Pyrofree vials product range consists of Type I clear glass vials of 2 mL, 5 mL, 10 mL and 20 mL, supplied with grey stoppers of 13 mm and 20 mm diameters, made of bromobutyl with Flurotec coating.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance